Cartilage-derived retinoic-acid-sensitive protein (CD-RAP) is a newly discovered 14 kD secreted protein expressed by chondrocytes. 1 Distribution analysis of CD-RAP mRNA has shown that during development in the mouse it is primarily expressed by chondroblasts and chondrocytes, and appears to be more chondrocyte-specific than the other molecules generally considered to be markers of the chondrocyte phenotype, such as link protein, aggrecan and type-II collagen. 1 In the mouse, CD-RAP is strongly expressed in the growth plate but is low in articular cartilage. 2 Its function in chondrocytes remains unknown except that it inhibits proliferation. 3 In malignant tissues, CD-RAP is also produced by chondrosarcoma, 4,5 melanoma 6 and mammary carcinoma. 7 CD-RAP is the same molecule which has been reported as melanoma inhibitory activity (MIA) and which was independently isolated from a metastatic melanoma cell line and so named because of its ability to inhibit DNA synthesis in such cell lines. 8 Recently, it was reported that CD-RAP/MIA is a useful serum marker for the detection of metastasis of melanoma. 9 Since the expression of CD-RAP is restricted in chondrocytes in normal tissue, 1-3 it may provide a means of monitoring the metabolic activity of cartilage.
Patients and Methods
We studied 49 patients with osteoarthritis (OA) of the knee and 79 with rheumatoid arthritis (RA). Of those with OA, 29 (mean age 61.7 years) had mild, 12 (mean age 67.1 years) moderate and 8 (mean age 69.0 years) severe OA. In the group with RA, 13 patients (mean age 61.3 years) had mild, 18 (mean age 63.1 years) moderate and 48 (mean age 65.0 years) severe RA. All the patients were divided into three groups of mild, moderate or severe according to classifications presented in previous reports. 10, 11 Briefly, the evaluation of joint destruction on plain anteroposterior radiographs and MRI was performed separately by each of three orthopaedic surgeons (SS, SK and MS), who had previously been instructed by the same radiologist. The mean of each grading repeated three times was compared among the three surgeons, and when discrepancies were noted, a grade was assigned after consensus had been reached. Samples of synovial fluid (SF) were aspirated from the knee of all the patients as part of their therapeutic programme. The SF was centrifuged at 3000 rpm for 20 minutes and the samples frozen and stored at -80°C until analysis. Quantitative analysis of CD-RAP in SF samples was performed using one-step ELISA with anti-human CD-RAP antibodies provided by Boehringer-Mannheim (Mannheim, Germany). Samples (20 l) or CD-RAP standard were incubated with 200 ml of reagent containing the antibodies in streptavidin-coated microtitre plates for 90 minutes with continuous shaking. After washing three times in phosphate-buffered saline (PBS), 200 l of 2,2'-aminodi-(3) ethylbenz-thiazoline sulphate (Boehringer-Mannheim) were added to the wells and absorbance was measured at 405 nm. Articular cartilage, subchondral bone, bony spur and synovium were obtained during knee arthroplasty surgery. The specimens were fixed in 10% formalin at room temperature for 24 hours, then embedded in paraffin. Deparaffinised sections were immersed three times in PBS for five minutes each. To show the localisation of CD-RAP, staining with Alcian Blue was performed. For immunostaining of CD-RAP, the activity of endogenous peroxidase was blocked by incubation with 0.2% hydrogen peroxide in methanol for 30 minutes and rinsed in PBS. The slides were then soaked in normal goat serum for 15 minutes for blocking and pretreated with 0.04% trypsin in PBS. The sections were incubated for 18 hours at 4°C with biotinylated CD-RAP antibody. After rinsing with PBS, they were treated by peroxidase-labelled streptavidin (Dako, Kyoto, Japan) for one hour at room temperature.
The reaction products were developed by immersing the sections in 3,3'-diaminobenzidine tetrahydrochloride solution containing 0.03% hydrogen peroxide. The nuclei were counterstained with Mayer's haematoxylin. For negative controls, the primary antibody was substituted with the antibody diluent. For positive controls, we used chondrosarcoma, which was stained positively (data not shown). Statistical analysis. All values were expressed as the mean ± standard deviation (SD). The Mann-Whitney U test was used for comparison between OA and RA groups and the Kruskal-Wallis test to determine whether concentrations differed significantly among the three groups of OA and RA. If a difference was noted the Sheffe test was used to compare the groups as a post-hoc test. A p value of < 0.05 was considered to be significant. Analysis of the data was performed using StatView 5.0 J software (SAS, Cary, North Carolina) on a personal computer.
Results

Concentrations of CD-RAP in SF.
We compared the concentration of CD-RAP in samples of SF from patients with OA and RA. The mean concentration of CD-RAP was 27.7 ± 5.9 ng/ml in the group with OA and 10.87 ± 8.6 ng/ ml in those with RA. The CD-RAP level in OA was significantly higher than that in RA (p < 0.01; Fig. 1 ). The level of CD-RAP in the group with mild OA was significantly higher than that in the moderate and the severe groups (p < 0.005; Fig. 2 ). In the group with RA, the level in the mild group was also significantly higher than that in the other groups (p < 0.01) and decreased with progression of the disease (p < 0.05; Fig. 3) . Immunolocalisation of CD-RAP. In order to determine the origin of CD-RAP in SF, we performed an immunohistochemical study on the specimens of articular cartilage, bony spur and synovium obtained during knee arthroplasty. Expression of CD-RAP was observed in the cytoplasm of chondrocytes in the bony spur (Fig. 4) , but very little was detected in the extracellular matrix. There Box plots of the percentile distribution of the concentration of CD-RAP in OA and RA. From the bottom up, the box indicates the 25th, 50th (median) and 75th percentiles, while the bars indicate the 10th and 90th percentiles, respectively. Open circles represent individual outliers, less than 10% in each direction. The level of CD-RAP in OA is significantly higher than in RA. Fig. 2 The concentration of CD-RAP in SF with OA. The level of CD-RAP in SF from the group with mild OA was significantly higher than that in the other OA groups. 
Discussion
This is the first report to show the existence of CD-RAP in synovial fluid and the possibility of using the level of CD-RAP as a joint marker. In order to assess damage to articular cartilage, several joint markers have been investigated. Type-II collagen is mainly expressed in chondrocytes and is the main component of articular cartilage. C-terminal type-II collagen propeptide is excised from type-II procollagen during the formation of type-II collagen, released to the extracellular matrix and finally excreted to the joint fluid. Shinmei et al 12 reported that the level of C-terminal type-II collagen propeptide in SF in OA is significantly higher than that in RA, reflecting biosynthesis of collagen in cartilage.
Other studies have indicated that matrix metalloproteinase (MMP)-3 may be the most important degradative enzyme in the breakdown of cartilage 13, 14 since it degrades proteoglycans and can activate other MMPs such as collagenases. MMP-3 in SF is mainly produced by synovial cells and is thought to be a marker for inflammation. 15 Proteoglycan is also the second component of articular cartilage in the extracellular matrix. Lohmander et al 16 showed that the level of proteoglycan in SF is very high immediately after injury to the anterior cruciate ligament. Shinmei et al 17 reported that the level of chondroitin sulphate isomer and chondroitin sulphate 4S:chondroitin sulphate-6S reflects the metabolism of proteoglycan in articular cartilage and could be used to diagnose joint diseases and to predict destruction of articular cartilage. We have shown that the level of CD-RAP in SF is more sensitive and more specific than the joint markers previously reported. Sakano et al 2 showed that CD-RAP is expressed in proliferating chondrocytes in growth plate and callus induced by fracture, but not in normal articular cartilage. However, when cartilage is damaged, the production of CD-RAP is induced to aid the remodelling of cartilage. Type-II collagen is cartilage-specific and abundantly produced in normal chondrocytes. Its existence in normal cartilage decreases its sensitivity and specificity as a joint marker. Since MMPs and proteoglycans are produced not only by chondrocytes but also by synovial cells, they were thought to be markers of inflammation rather than of cartilage metabolism. 15 To date, the func- The concentration of CD-RAP in SF with RA. The level of CD-RAP in SF from the group with mild RA was highest and decreased as the disease progressed. The expression of CD-RAP in newly formed fibrocartilage. tion of CD-RAP remains unknown and there is no information as to whether it has an effect on inflammation and/or the destruction of cartilage. In our results the SD is low compared with that in other studies of this type. We used not only radiography but also MRI to define the groups. Radiography shows only bone and morphology but MRI provides information on the quality of the bone marrow and cartilage. This may explain the low value of the SD. CD-RAP is the same molecule as has been reported as melanoma inhibitory activity (MIA). CD-RAP/MIA is detected in melanoma and mammary carcinoma 7, 17, 18 and can be used to monitor activity of the tumour. 9 Increased serum concentrations were found in rheumatic diseases associated with joint destruction. 19 Recently, Neidhart et al 20 have reported that after marathon running, the serum level of CD-RAP/MIA is significantly increased. They suggest that CD-RAP/MIA is a marker for certain aspects of joint metabolism and damage in sport. We have shown that the level of CD-RAP in synovial fluid is sensitive and specific to the degree of joint disease. We consider that expression of CD-RAP reflects repair of articular cartilage and decreases with destruction of the cartilage. The concentration of CD-RAP may be useful for monitoring the degree of restorative reaction. No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.
